RxDoctor Payments Data

Nathan Bahr, MD

Infectious Disease · Minneapolis, MNNPI 1609006048

Payments from drug & device makers

What this record shows

That places this record below the midpoint for infectious disease clinicians in MN, where the typical reported total is $40.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$344,865in research payments, 2019–2025

Across 16 payments — averaging $21,554 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Karyopharm Therapeutics Inc.$345K

How this compares

$0 in reported general payments places this provider in the 20th percentile of 157 infectious disease providers in Minnesota.

See all infectious disease providers in Minnesota

Medicare billing

Part B allowed, 2024
$4,763
Medicare patients
20
Services billed
37

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other infectious disease in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →